Influenza vaccine live, intranasal - Biologic Drug Details

Summary for influenza vaccine live, intranasal

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for influenza vaccine live, intranasal Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for influenza vaccine live, intranasal Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Medimmune, Llc	FLUMIST, FLUMIST QUAD	influenza vaccine live, intranasal	Suspension	125020		2018-04-06	DrugPatentWatch analysis and company disclosures
Medimmune, Llc	FLUMIST, FLUMIST QUAD	influenza vaccine live, intranasal	Suspension	125020		2021-04-11	DrugPatentWatch analysis and company disclosures
Medimmune, Llc	FLUMIST, FLUMIST QUAD	influenza vaccine live, intranasal	Suspension	125020		2022-05-02	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for influenza vaccine live, intranasal Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Market Dynamics and Financial Trajectory for the Influenza Vaccine Live, Intranasal

Last updated: February 20, 2026

What Is the Current Market Size and Growth Outlook?

The global influenza vaccine market was valued at approximately USD 4.8 billion in 2022, with projections reaching USD 8.1 billion by 2028, growing at a compound annual growth rate (CAGR) of 9.0%. The intranasal live attenuated influenza vaccine (LAIV) segment accounts for about 12-15% of recent market share, driven by the ease of administration and increased vaccination compliance.

What Are the Key Drivers Influencing Market Expansion?

Increasing Influenza Burden

Annual influenza infections affect 5-15% of the global population, causing 290,000 to 650,000 respiratory deaths. The disease burden supports ongoing demand for effective, accessible vaccines.

Preference for Intranasal Delivery

Intranasal LAIV offers advantages over injectable vaccines: needle-free administration, suitability for children and needle-phobic individuals, and potential for mucosal immunity. Regulatory approval in multiple jurisdictions has facilitated broader adoption.

Advances in Vaccine Technology

Technological improvements include enhanced strain stability, improved immunogenicity, and better cold chain management. These innovations contribute to increased vaccine uptake.

Vaccination Campaigns and Policies

Public health initiatives emphasize intranasal vaccines in pediatric vaccination programs. WHO recommends annual vaccination, expanding global market potential.

COVID-19 Impact

The pandemic amplified awareness of respiratory illnesses, increasing demand for vaccines. Distribution and demand for influenza vaccines have expanded, influencing market growth.

What Are the Barriers and Challenges?

Limited Manufacturing Capacity

Complex production processes for live attenuated vaccines require extensive quality controls, constraining supply expansion. Manufacturing bottlenecks limit market penetration in certain regions.

Regulatory Landscape

Limited approvals outside North America and Europe delay global distribution. Variability in regulatory standards complicates entry into emerging markets.

Variability in Efficacy

In some seasons, LAIV shows lower effectiveness compared to inactivated vaccines, especially among adults, affecting physician and patient preferences.

Cold Chain Requirements

The need for strict cold chain logistics increases distribution costs, particularly in developing countries.

Who Are the Market Players and Their Strategies?

Leading Companies

• Sanofi Pasteur: Dominates the market with Flumist (approved in multiple countries). Focuses on technological enhancements and expanding geographic reach.
• AbbVie (formerly MedImmune): Produces FluMist Quadrivalent, emphasizing pediatric vaccination programs.
• Seqirus: Invests in next-generation intranasal vaccines with improved thermostability.
• CSL Limited: Developing novel live attenuated formulations.

Strategic Moves

• Expanding manufacturing capacities during pandemic preparedness.
• Entering partnerships for regional approval and distribution.
• Developing thermostable formulations to address cold chain limitations.

What Is the Financial Trajectory Anticipated for the Next Five Years?

Revenue Projections

Year-over-year growth projections suggest a jump from USD 0.6 billion in 2022 to USD 1.4 billion in 2028, corresponding to a CAGR of 16.4%. The disparity between the overall influenza vaccine market and intranasal LAIV reflects ongoing adoption patterns.

Investment Trends

Pharmaceutical companies are increasing R&D spending on thermostable and broad-spectrum intranasal vaccines, with investments surpassing USD 500 million annually since 2020.

Cost Considerations

Manufacturing costs for LAIV are higher than inactivated vaccines. Nevertheless, the potential for higher compliance and vaccination rates supports premium pricing strategies.

Market Expansion Opportunities

Growing acceptance in pediatric and vulnerable populations, plus increased distribution efforts in emerging markets, could elevate revenues substantially. Entry into new markets depends on regulatory approvals and logistical infrastructure.

What Regulatory and Policy Developments Are Shaping the Market?

• FDA approvals: The US FDA approved Flumist Quadrivalent in 2014 for individuals aged 2–49.
• EMA authorizations: The European Medicines Agency authorized intranasal vaccines for children aged 2–17.
• Global health policies: WHO recommends universal influenza vaccination, influencing national immunization programs and market demand.

Key Takeaways

• The influenza vaccine market, valued at USD 4.8 billion in 2022, is expected to reach USD 8.1 billion by 2028.
• Intranasal LAIV captures a growing segment, valued at roughly 12-15% of the market.
• Demand boosts from increased influenza awareness, technological innovations, and policy promotion.
• Challenges include manufacturing capacity limits, regulatory variability, and cold chain logistics.
• Revenue forecast indicates a CAGR of approximately 16.4%, driven by expanding vaccination programs and R&D investments.

FAQs

1. What factors limit the global adoption of intranasal influenza vaccines?
Manufacturing complexity, supply chain requirements, variable efficacy data, and regulatory hurdles restrict widespread use.

2. Which regions show the highest growth potential for LAIV?
Emerging markets in Asia-Pacific and Latin America possess high growth potential due to expanding immunization programs and unmet needs.

3. What technological innovations are improving LAIV prospects?
Thermostable formulations, enhanced strain stability, and broader-spectrum vaccines improve efficacy and logistical feasibility.

4. How do regulatory differences impact market growth?
Diverse approval processes delay market entry, especially in regions lacking clear pathways for live attenuated vaccines.

5. What strategic moves could accelerate market growth?
Expanding manufacturing capacity, securing regulatory approvals, investing in thermostability, and forming regional distribution partnerships.

---

References

[1] MarketWatch. (2023). Influenza vaccine market analysis.
[2] Grand View Research. (2022). Influenza vaccine market report.
[3] World Health Organization. (2022). Influenza vaccine recommendation updates.
[4] Statista. (2023). Forecasts for global vaccine sales.
[5] FDA. (2014). Flumist Quadrivalent approval documentation.